News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
825,543 Results
Type
Article (75765)
Company Profile (499)
Press Release (749258)
Multimedia
Podcasts (181)
Webinars (29)
Section
Business (221268)
Career Advice (3322)
Deals (38743)
Drug Delivery (147)
Drug Development (88752)
Employer Resources (192)
FDA (18230)
Job Trends (16793)
News (380092)
Policy (38651)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3012)
Academic (1)
Accelerated approval (37)
Adcomms (36)
Allergies (156)
Alliances (55800)
ALS (184)
Alzheimer's disease (1817)
Antibody-drug conjugate (ADC) (359)
Approvals (18417)
Artificial intelligence (612)
Autoimmune disease (183)
Automation (44)
Bankruptcy (395)
Best Places to Work (12530)
BIOSECURE Act (23)
Biosimilars (209)
Biotechnology (328)
Bladder cancer (167)
Brain cancer (67)
Breast cancer (684)
Cancer (5180)
Cardiovascular disease (461)
Career advice (2829)
Career pathing (42)
CAR-T (314)
CDC (64)
Celiac Disease (2)
Cell therapy (838)
Cervical cancer (38)
Clinical research (75080)
Collaboration (1895)
Company closure (4)
Compensation (1210)
Complete response letters (78)
COVID-19 (2998)
CRISPR (105)
C-suite (936)
Cystic fibrosis (155)
Data (6492)
Decentralized trials (2)
Denatured (65)
Depression (158)
Diabetes (544)
Diagnostics (7247)
Digital health (53)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (296)
Drug pricing (224)
Drug shortages (33)
Duchenne muscular dystrophy (249)
Earnings (91184)
Editorial (68)
Employer branding (23)
Employer resources (167)
Events (130715)
Executive appointments (1058)
FDA (21512)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1593)
Gene editing (224)
Generative AI (55)
Gene therapy (679)
GLP-1 (1144)
Government (5380)
Grass and pollen (8)
Guidances (388)
Healthcare (20799)
HIV (68)
Huntington's disease (51)
IgA nephropathy (89)
Immunology and inflammation (306)
Immuno-oncology (70)
Indications (119)
Infectious disease (3307)
Inflammatory bowel disease (212)
Inflation Reduction Act (15)
Influenza (130)
Intellectual property (263)
Interviews (616)
IPO (17678)
IRA (59)
Job creations (4649)
Job search strategy (2325)
JPM (68)
Kidney cancer (17)
Labor market (91)
Layoffs (660)
Leadership (42)
Legal (9653)
Liver cancer (99)
Longevity (17)
Lung cancer (701)
Lymphoma (393)
Machine learning (45)
Management (64)
Manufacturing (880)
MASH (179)
Medical device (15032)
Medtech (15092)
Mergers & acquisitions (22166)
Metabolic disorders (1439)
Multiple sclerosis (174)
NASH (23)
Neurodegenerative disease (372)
Neuropsychiatric disorders (106)
Neuroscience (3194)
Neurotech (1)
NextGen: Class of 2026 (7511)
Non-profit (5088)
Now hiring (64)
Obesity (703)
Opinion (341)
Ovarian cancer (172)
Pain (220)
Pancreatic cancer (243)
Parkinson's disease (308)
Partnered (37)
Patents (534)
Patient recruitment (523)
Peanut (62)
People (66025)
Pharmaceutical (99)
Pharmacy benefit managers (33)
Phase 1 (23309)
Phase 2 (32749)
Phase 3 (24633)
Pipeline (5621)
Policy (346)
Postmarket research (3134)
Preclinical (10303)
Press Release (72)
Prostate cancer (256)
Psychedelics (60)
Radiopharmaceuticals (309)
Rare diseases (962)
Real estate (7083)
Recruiting (78)
Regulatory (28500)
Reports (57)
Research institute (2723)
Resumes & cover letters (529)
Rett syndrome (28)
RNA editing (21)
RSV (90)
Schizophrenia (162)
Series A (264)
Series B (205)
Service/supplier (18)
Sickle cell disease (106)
Special edition (28)
Spinal muscular atrophy (175)
Sponsored (49)
Startups (4234)
State (2)
Stomach cancer (21)
Supply chain (114)
Tariffs (101)
The Weekly (115)
Vaccines (1177)
Venture capital (101)
Weight loss (481)
Women's health (96)
Worklife (22)
Date
Today (51)
Last 7 days (615)
Last 30 days (2519)
Last 365 days (32040)
2026 (4312)
2025 (32431)
2024 (37574)
2023 (42459)
2022 (53819)
2021 (58599)
2020 (57497)
2019 (50990)
2018 (38853)
2017 (36511)
2016 (37256)
2015 (43341)
2014 (37501)
2013 (33198)
2012 (35212)
2011 (35435)
2010 (34250)
Location
Africa (1142)
Alabama (93)
Alaska (7)
Arizona (328)
Arkansas (13)
Asia (49427)
Australia (8381)
California (11838)
Canada (3394)
China (1204)
Colorado (500)
Connecticut (515)
Delaware (356)
Europe (112479)
Florida (1762)
Georgia (384)
Hawaii (4)
Idaho (67)
Illinois (971)
India (75)
Indiana (556)
Iowa (23)
Japan (453)
Kansas (133)
Kentucky (44)
Louisiana (29)
Maine (84)
Maryland (1478)
Massachusetts (8650)
Michigan (357)
Minnesota (671)
Mississippi (6)
Missouri (142)
Montana (36)
Nebraska (29)
Nevada (128)
New Hampshire (86)
New Jersey (3179)
New Mexico (33)
New York (3121)
North Carolina (1639)
North Dakota (10)
Northern California (5723)
Ohio (360)
Oklahoma (23)
Oregon (47)
Pennsylvania (2368)
Puerto Rico (24)
Rhode Island (50)
South America (1533)
South Carolina (69)
South Dakota (1)
Southern California (4596)
Tennessee (182)
Texas (1842)
United States (42530)
Utah (356)
Vermont (1)
Virginia (292)
Washington D.C. (86)
Washington State (982)
West Virginia (4)
Wisconsin (134)
Wyoming (2)
825,543 Results for "genomma lab internacional s a b de c v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its First Quarter 2024 Earnings Results on Wednesday, April 24, 2024, after the Mexican Stock Exchange (BMV) close.
April 4, 2024
·
2 min read
Business
Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter and Full Year 2023 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its Fourth Quarter and Full Year 2023 results on Wednesday, February 21, 2024, after the Mexican Stock Exchange (BMV) close.
January 23, 2024
·
2 min read
Business
Genomma Lab Internacional Announces Results for the First Quarter 2024
Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter of 2024.
April 24, 2024
·
5 min read
Business
Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2023 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its Third Quarter 2023 results on Wednesday, October 25, 2023, after the Mexican Market (BMV) close.
October 4, 2023
·
2 min read
Genomma Lab Internacional Announces Eighth Dividend Payment
Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024.
June 13, 2024
·
4 min read
Business
Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2023.
February 21, 2024
·
5 min read
Business
Genomma Lab Internacional Reports Third Quarter 2023 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2023.
October 25, 2023
·
4 min read
Genomma Lab Internacional Announces Seventh Dividend Payment - March 13, 2024
Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024.
March 13, 2024
·
3 min read
Policy
Genomma Lab’s ESG Rating Upgraded to A
Genomma Lab Internacional, S.A.B. de C.V. announced that MSCI, one of the world’s largest providers of indices for tracking companies according to environmental, social and governance criteria, upgraded Genomma’s MSCI ESG Rating to A from BBB.
February 28, 2024
·
4 min read
Business
Genomma Lab Internacional Reports Second Quarter 2023 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the second quarter ended June 30, 2023.
July 26, 2023
·
4 min read
1 of 82,555
Next
